Intellia Therapeutics, Inc (NTLA) Stock Price
NTLAStock
$11.42−54.16%52W
Market Cap$1.60B
P/E—
PEG Ratio—
Div yield—
Beta1.83
NTLA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-32.64%
Price vs S&P 500 (4W)-5.22%
VGM Score40.31
NTLA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.78 | -$0.80 | -1.95%(-$0.02) | |
| Q1 2026 | -$0.90 | -$0.81 | +9.80%(+$0.09) | |
| Q4 2025 | -$0.96 | -$0.83 | +13.71%(+$0.13) | |
| Q3 2025 | -$0.98 | -$0.92 | +6.57%(+$0.06) | |
| Q2 2025 | -$1.01 | -$0.98 | +2.51%(+$0.03) |
NTLA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.64
3.67
3.54
3.58
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
NTLAIntellia Therapeutics, Inc | D | D | C | 26.9x | 12.6% | — | — | $11.42 |
| IDXXIdexx Laboratories Inc | D | B | B | 9.7x | 12.8% | 62.5% | 14.3% | $560.36 |
| LNTHLantheus Holdings, Inc | C | B | B | 4.2x | 2.4% | 61.0% | 40.7% | $99.70 |
| NEOGNeogen Corp | C | C | A | 2.9x | -0.3% | 47.4% | — | $11.81 |
| CLDXCelldex Therapeutics, Inc | F | F | C | 13683.0x | -97.3% | 17.6% | — | $27.53 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | 0.3x | -2.5% | 44.6% | — | $12.91 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | 36.8x | -89.3% | — | — | $6.38 |
| MYGNMyriad Genetics Inc | C | C | D | 0.5x | -3.2% | 68.8% | — | $3.98 |
| TKNOAlpha Teknova, Inc. Common Stock | D | C | B | 8.7x | 12.3% | 34.6% | — | $7.08 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | C | F | 34.0x | -5.7% | 89.0% | — | $3.13 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | C | 59.0x | -60.8% | 48.3% | — | $3.01 |
About Intellia Therapeutics, Inc
Intellia Therapeutics develops CRISPR-based gene therapies to treat genetically defined diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, and sickle cell disease. The company employs both in vivo and ex vivo therapeutic approaches across its pipeline. Strategic partnerships with Regeneron and Novartis provide clinical and commercial validation for its gene-editing platform.